The Principal is the recipient of the 2017 Julia Levy Award from the Chemical Institute of Canada, the 2016 Leadership Award from Life Sciences Ontario and the 2012 Gold Leaf Award for Industry Leadership from BIOTECanada.Cresswell is an advisory and consultancy providing assistance, direction and governance principally to development-stage public and private companies in the life sciences and early-stage and established companies in multiple fields. Formerly a Governor of the Toronto Stock Exchange, the Principal has been a member of the Awards Selection Committee of Canada's Network of Centers of Excellence, the Multidisciplinary Assessment Committee of the Canada Foundation for Innovation, and of the Ontario Biotechnology Advisory Board.He was the Founding Chairman of YM BioSciences Inc and CEO from 1998-2010, Founding Chairman of Formation Biologics, Executive Chairman of Stem Cell Therapeutics (now Trillium Therapeutics), a board member of Avivagen Inc, lead director of Diamedica Inc. and is currently a board member of Life Sciences Ontario. In 1992 he created the first Investment banking team in Canada providing research into and financing of life-sciences companies resulting in the creation of numerous companies including Drug Royalty Corporation and YM BioSciences Inc. Drug Royalty was the first public company in the world to invest in biopharmaceuticals through the royalty stream and YM became the first company from any major-market country to joint venture with the Cuban government for the commercialization of its biopharmaceuticals, the first company in the world to achieve Orphan Drug Designation from the FDA for a Cuban-origin drug, clearance from the FDA for the treatment of US patients with such drugs and the first to receive approval from the US Office of Foreign Assets Control to import Cuban-origin therapeutics into the United States.